SageMedic

Executive Summary

SageMedic is a San Diego-based diagnostics company pioneering next-generation precision medicine for cancer care with its flagship SAGE Oncotest™. This functional tumor profiling assay uses live patient-derived 3D microtumors to test a curated panel of FDA-approved drugs, identifying the most effective therapy for each patient in just 7–10 days. By enabling personalized treatment selection, the test aims to improve outcomes, reduce side effects, and lower healthcare costs compared to traditional trial-and-error approaches. Founded in 2018, the company has reached an 'Approved' stage, suggesting regulatory clearance or clinical validation, positioning it to disrupt the oncology diagnostics market. With the growing emphasis on precision medicine and the need for rapid, actionable drug sensitivity data, SageMedic addresses a critical gap in cancer care, potentially becoming a standard tool for oncologists. Its innovative platform leverages 3D cell culture technology to mimic tumor microenvironments, offering higher predictive accuracy than genomic profiling alone. The company targets the large and expanding market of oncology treatment decisions, where poor therapy response rates remain a significant challenge.

Upcoming Catalysts (preview)

• Q3 2026Publication of clinical validation study in peer-reviewed journal70% success
• Q2 2026Strategic partnership with major cancer center or hospital network60% success
• Q4 2026CMS reimbursement coverage decision for SAGE Oncotest50% success